Name | Number of supported studies | Average coverage | |
---|---|---|---|
glutamatergic neuron | 6 studies | 26% ± 13% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 28% ± 10% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
brain | 94% | 19854.30 | 2488 / 2642 | 100% | 48.71 | 704 / 705 |
lymph node | 0% | 0 | 0 / 0 | 100% | 19.87 | 29 / 29 |
spleen | 95% | 1859.18 | 229 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 93% | 3.45 | 42 / 45 |
peripheral blood | 91% | 2936.49 | 850 / 929 | 0% | 0 | 0 / 0 |
lung | 2% | 33.58 | 13 / 578 | 84% | 2.73 | 971 / 1155 |
pancreas | 0% | 0 | 0 / 328 | 86% | 3.63 | 153 / 178 |
breast | 2% | 28.62 | 7 / 459 | 83% | 2.48 | 930 / 1118 |
esophagus | 8% | 140.88 | 117 / 1445 | 73% | 2.26 | 133 / 183 |
bladder | 0% | 0 | 0 / 21 | 81% | 3.63 | 406 / 504 |
uterus | 0% | 0 | 0 / 170 | 79% | 2.81 | 361 / 459 |
adrenal gland | 1% | 31.84 | 2 / 258 | 77% | 13.02 | 178 / 230 |
skin | 0% | 0 | 0 / 1809 | 76% | 3.22 | 360 / 472 |
stomach | 0% | 0 | 0 / 359 | 74% | 2.77 | 211 / 286 |
intestine | 8% | 150.63 | 76 / 966 | 65% | 2.49 | 345 / 527 |
thymus | 4% | 65.05 | 27 / 653 | 68% | 3.26 | 414 / 605 |
kidney | 0% | 0 | 0 / 89 | 72% | 2.09 | 645 / 901 |
prostate | 2% | 27.89 | 5 / 245 | 52% | 0.90 | 259 / 502 |
liver | 0% | 0 | 0 / 226 | 45% | 0.86 | 181 / 406 |
heart | 40% | 1003.08 | 347 / 861 | 0% | 0 | 0 / 0 |
ovary | 0% | 0 | 0 / 180 | 32% | 0.58 | 137 / 430 |
eye | 0% | 0 | 0 / 0 | 25% | 0.57 | 20 / 80 |
muscle | 20% | 286.33 | 157 / 803 | 0% | 0 | 0 / 0 |
adipose | 5% | 78.65 | 62 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 0% | 7.73 | 5 / 1335 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0042177 | Biological process | negative regulation of protein catabolic process |
GO_0090630 | Biological process | activation of GTPase activity |
GO_0045860 | Biological process | positive regulation of protein kinase activity |
GO_0030036 | Biological process | actin cytoskeleton organization |
GO_0016197 | Biological process | endosomal transport |
GO_0015031 | Biological process | protein transport |
GO_0043524 | Biological process | negative regulation of neuron apoptotic process |
GO_0016020 | Cellular component | membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0090543 | Cellular component | Flemming body |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005768 | Cellular component | endosome |
GO_0005634 | Cellular component | nucleus |
GO_0141038 | Molecular function | phosphatidylinositol 3-kinase activator activity |
GO_0035014 | Molecular function | phosphatidylinositol 3-kinase regulator activity |
GO_0019901 | Molecular function | protein kinase binding |
GO_0005096 | Molecular function | GTPase activator activity |
GO_0005525 | Molecular function | GTP binding |
GO_0030295 | Molecular function | protein kinase activator activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
GO_0003924 | Molecular function | GTPase activity |
Gene name | AGAP2 |
Protein name | ArfGAP with GTPase domain, ankyrin repeat and PH domain 2 Arf-GAP with GTPase, ANK repeat and PH domain-containing protein 2 (AGAP-2) (Centaurin-gamma-1) (Cnt-g1) (GTP-binding and GTPase-activating protein 2) (GGAP2) (Phosphatidylinositol 3-kinase enhancer) (PIKE) |
Synonyms | CENTG1 KIAA0167 |
Description | FUNCTION: GTPase-activating protein (GAP) for ARF1 and ARF5, which also shows strong GTPase activity. Isoform 1 participates in the prevention of neuronal apoptosis by enhancing PI3 kinase activity. It aids the coupling of metabotropic glutamate receptor 1 (GRM1) to cytoplasmic PI3 kinase by interacting with Homer scaffolding proteins, and also seems to mediate anti-apoptotic effects of NGF by activating nuclear PI3 kinase. Isoform 2 does not stimulate PI3 kinase but may protect cells from apoptosis by stimulating Akt. It also regulates the adapter protein 1 (AP-1)-dependent trafficking of proteins in the endosomal system. It seems to be oncogenic. It is overexpressed in cancer cells, prevents apoptosis and promotes cancer cell invasion. . |
Accessions | J3KNM6 H0YHB1 Q99490 ENST00000547588.6 F8VVT9 ENST00000549129.1 ENST00000328568.9 ENST00000257897.7 [Q99490-2] |